THE YEAR IN SHORT

AddLife 2021

2021 was a successful year for AddLife, with seven acquisitions and an all-time high in revenue and profit. The acquisitions are expected to contribute total annual sales of approximately SEK 3,300 million. The COVID-19 pandemic has continued to have a significant impact on the Life Science market and the business situation. Sales increased by 52 percent, of which organic growth amounted to 11 percent.

The significant increase in sales in combination with continued good cost control led to a positive earnings effect where EBITA increased by 59 percent compared with 2020. The result has generated a strong positive operating cash flow, which enables further investments in acquisitions and development for future growth.

The business situation in all markets was affected by the COVID-19 pandemic. The companies within Labtech have delivered large quantities of COVID-19 tests. The increase in sales within Medtech is primarily driven by acquisitions as we had limited sales of COVID-19 related products in the business area.